Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_assertion type Assertion NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_head.
- NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_assertion description "[Eligible patients were older than 18 years of age; had histologically or cytologically confirmed stage IIIB-IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performance status of 0-1; had not received previous therapy with either a MEK inhibitor or docetaxel; and had adequate bone marrow, renal, and liver function.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_provenance.
- NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_assertion evidence source_evidence_literature NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_provenance.
- NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_assertion SIO_000772 23200175 NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_provenance.
- NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_assertion wasDerivedFrom befree-20150227 NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_provenance.
- NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_assertion wasGeneratedBy ECO_0000203 NP646189.RAYh8X58YTDGIOwWQlQUEyuQc05b8QqK-F-cs1fo9M_1Q130_provenance.